News
The Phase III NIMBLE trial met its primary and key secondary endpoints, with cemdisiran monotherapy showing robust efficacy ...
Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of ...
Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback